相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation
Ping Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development
Sandhya Girish et al.
AAPS Journal (2011)
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Malcolm Rowland et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review
P. Zhao et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Disease-Drug-Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis
C. Schmitt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Clinical pharmacology as a cornerstone of orphan drug development
Edward D. Bashaw et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Transporter Pharmacogenetics and Statin Toxicity
M. Niemi
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Therapeutic Protein-Drug Interactions and Implications for Drug Development
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Transporters in drug development: advancing on the Critical Path
Shiew-Mei Huang et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1
P. Annaert et al.
XENOBIOTICA (2010)
When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
Odette A. Fahmi et al.
DRUG METABOLISM AND DISPOSITION (2009)
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates
Masoud Jamei et al.
DRUG METABOLISM AND PHARMACOKINETICS (2009)
The In Silico Child: Using Simulation to Guide Pediatric Drug Development and Manage Pediatric Pharmacotherapy
Stephanie Laeer et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
Takao Watanabe et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Pediatric antihypertensive trial failures - Analysis of end points and dose range
Daniel K. Benjamin et al.
HYPERTENSION (2008)
Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process
Shiew-Mei Huang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Improving pediatric dosing through pediatric initiatives: What we have learned
William Rodriguez et al.
PEDIATRICS (2008)
Drug interaction studies: Study design, data analysis, and implications for dosing and labeling
S-M Huang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
分享论文
